-
Mashup Score: 2Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials - The Lancet Oncology in conversation with - 4 day(s) ago
Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.
Source: www.buzzsprout.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 11Rethinking metastatic brain cancer as a CNS disease - 4 day(s) ago
Advances in molecular biology, genetics, and epigenetics have refined our understanding of metastatic brain cancer and underscored the need for better classification and targeted approaches. The heterogeneity of brain metastases highlights the differences from their primary source of origin and contributes to therapeutic resistance. Before colonising the brain, tumour cells acquire specialised proficiencies that enable them to capitalise on the unique microenvironment of the brain. The tumour cells further orchestrate key adaptations to adjust to the brain microenvironment by manipulating the blood–brain barrier, evading immune surveillance, rewiring metabolic profiles, and reprogramming astrocytes.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 31
Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment landscape for a wide variety of malignancies. Older adults represent a large and rapidly growing demographic, among whom ICIs are widely prescribed. Management of ICI-associated toxicity among older adults, particularly in the presence of frailty and comorbidity, poses unique challenges. In this Policy Review, developed by the International Society of Geriatric Oncology (SIOG), we offer an evidence-based framework for health-care providers, caregivers, and policy makers for treating older adults with ICIs, focusing on unique considerations for this population that are not adequately addressed by existing guidelines, and expanding them to encompass geriatric oncology principles.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5
The combination of ibrutinib–venetoclax significantly improved progression-free survival compared with ibrutinib–placebo in patients with relapsed or refractory MCL. The safety profile was consistent with known safety profiles of the individual drugs. These findings suggest a positive benefit–risk profile for ibrutinib–venetoclax treatment.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 9
These data highlight the need for a better understanding of the most appropriate treatment for patients who have progressed on a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, and the optimal sequencing of chemotherapy and PARP inhibitors in advanced ovarian cancer.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 46The Lancet Oncology - 5 day(s) ago
Access articles from The Lancet Oncology, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Fires and their smouldering health effects - 5 day(s) ago
In January, 2025, six wildfires broke out and spread rapidly across the greater Los Angeles region in California, USA. Fanned by the strong Santa Ana winds, these raging infernos have caused unprecedented devastation, with almost 40 000 acres burned, more than 12 000 buildings and other structures destroyed, entire neighbourhoods decimated, at least 27 people killed and thousands more made homeless, as well as immeasurable losses of vegetation and wildlife. At the time of writing, the two largest fires are still not completely contained.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 10
Against all odds, in a victory of data over opinion, and after the determined work of the Health and Social Care Select Committee in collecting and acting on the evidence, Wes Streeting (Secretary of State for Health and Social Care, UK) finally announced on Dec 19, 2024, the decision of the UK Government to publish a National Cancer Control Plan in 2025.1 The International Cancer Benchmarking Partnership (ICBP) has shown unequivocally that countries with consistent national cancer plans have better cancer outcomes than those that do not.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 46The Lancet Oncology - 5 day(s) ago
Access articles from The Lancet Oncology, covering topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 7
There is an urgent need to globally strengthen cancer-care systems considering projections that cancer cases will substantially increase during the coming years, said global leaders during a forum discussion on cancer care at the annual World Economic Forum in Davos, Switzerland, on Jan 22, 2025.
Source: www.thelancet.comCategories: General Medicine News, Oncologists1Tweet
@csoncol Listen to our latest podcast episode: In conversation with Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials https://t.co/crXzJxhrvh